Keyphrases
Mouse Model
100%
Disability
100%
Fullerene
100%
Progressive multiple Sclerosis
100%
Axonal Loss
100%
Disease Progression
40%
Spinal Cord
40%
NMDA Receptor Antagonist
40%
Glutamine Synthetase
40%
Multiple Sclerosis
20%
Astrocytes
20%
Therapeutic Approaches
20%
Neurodegenerative Diseases
20%
Antioxidant
20%
Neuroprotection
20%
Treatment Effect
20%
Disease Onset
20%
CD11b+
20%
Neuroprotective Effect
20%
Oxidative Damage
20%
Axonal Degeneration
20%
Insults
20%
Infiltration
20%
Glutamate Transporter 1 (GLT-1)
20%
Neurological Impairment
20%
White Matter
20%
Progressive EAE
20%
Axonal Damage
20%
Chronic Progressive
20%
Axonal Demyelination
20%
Myelin Oligodendrocyte Glycoprotein
20%
NOD Mice
20%
Excitotoxic
20%
Water-soluble Fullerene Derivatives
20%
Antigen-specific T Cell Response
20%
Transporter Expression
20%
Chemokine (C-C motif) Ligand 2 (CCL2)
20%
Glutamate-induced Injury
20%
EAE Model
20%
Clinical Progression
20%
Pharmacology, Toxicology and Pharmaceutical Science
Mouse Model
100%
Multiple Sclerosis
100%
Fullerene
100%
Mouse
40%
Injury
40%
Disease Exacerbation
40%
N Methyl Dextro Aspartic Acid Receptor Blocking Agent
40%
Glutamate Ammonia Ligase
40%
Disease
20%
Antioxidant
20%
Degenerative Disease
20%
Demyelination
20%
Neuroprotective Agent
20%
Neuroprotection
20%
Glutamic Acid
20%
Glutamate Transporter
20%
Fullerene Derivative
20%
Nerve Fiber Degeneration
20%
Nonobese Diabetic Mouse
20%
Myelin Oligodendrocyte Glycoprotein
20%
Neuroscience
Multiple Sclerosis
100%
NMDA Receptor Antagonist
50%
Glutamate Ammonia Ligase
50%
In Vitro
25%
Astrocyte
25%
Neurodegenerative Disorder
25%
T Cell
25%
Neuroprotection
25%
Neuroprotective Agent
25%
Glutamic Acid
25%
Glutamate Transporter
25%
Antioxidant
25%
Nerve Fiber Degeneration
25%
CCL2
25%
Myelin Oligodendrocyte Glycoprotein
25%
Axonal Degeneration
25%